$AMGN news
The latest AMGN stock news: headlines, filings, AI summaries and sentiment for $AMGN, updated around the clock.
- Amgen Shares Decline Following Late-Stage Trial Results for Sjögren's Disease Drug
- AbCellera Reports Q3 2026 Results and Positive Phase II Data for ABCL635
- Amgen Develops Monthly Obesity Drug MariTide to Challenge Weekly Injection Market
- Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
- BeOne Medicines Reports Strong Q3 2026 Results and Raises Full-Year Revenue Guidance
- Major US Indexes and Biotech Sector Rally Following Election and Strong Earnings
- Amgen Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
- AMGEN INC - 10-Q Filing
- Amgen Raises 2026 Earnings Guidance Following Strong Q3 Revenue Growth
- Amgen Raises 2026 Revenue and Profit Guidance Following Q3 Earnings Beat
- Amgen Reports Q3 Earnings Beat with $10.4 Billion in Revenue
- AMGEN INC - 8-K Filing
- Teva Pharmaceutical Industries Reports Q3 2026 Results with Raised Full-Year Guidance
- Market Analysis: AI Sector Rebound and Political Risks Surrounding Data Center Rhetoric
- Key Corporate Earnings Scheduled After Market Close on Tuesday
- Jazz Pharmaceuticals Reports Q3 2026 Results with Revenue Growth and Raised Guidance
- Market Outlook: Apple Earnings, Tech Sector Declines, and Midterm Election Impact on AI Infrastructure
- Amgen Q3 Earnings Preview: Focus on Established Product Revenue Erosion
- Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment
- FDA Issues Warning Letter to Amgen Over Misleading Vectibix Advertisement
- Amgen vs. Vertex Pharmaceuticals: A Comparison of Revenue Scale and Growth Trajectories
- Amgen's Imdelltra Combination Therapy Reduces Death Risk by 58% in Extensive-Stage Small Cell Lung Cancer
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- Pfizer Announces $0.43 Quarterly Dividend
- AbbVie Included in New 340B Rebate Pilot Program
- Teva Receives FDA Approval for Biosimilar Version of Amgen's Xgeva
- Novo Nordisk Stock Falls After Outlining Long-Term Growth Targets
- Stocks Making Significant Moves Midday: Lennar, Amgen, Vicor and Others
- Amgen Reports Positive Late-Stage Trial Results for Experimental Drug Targeting Sjögren’s Disease
- Dow Slips as Oil Stocks Fall Amid U.S.-Iran Hopes; Homebuilders and Retailers Rise
- Morgan Stanley Highlights Amgen's Competitive Position After Novartis Heart Drug Trial Failure
- Novartis' Failed Cholesterol Drug Trial Raises Questions About Amgen and Eli Lilly's Experimental Treatments
- Amgen Stock Drops Sharply Amid Novartis' Lp(a)-Lowering Drug Failure
- Novartis' Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Novartis' Pelacarsen Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Amgen Shares Drop After Novartis' Lp(a)-Lowering Drug Fails in Trial
- UnitedHealth, Amgen, CooperCompanies Highlight Key Healthcare News
- Karyopharm delays debt payment; Amgen explores expanded use for Imdelltra
- Positive Lung Cancer Trial Results for Amgen's Imdelltra and AstraZeneca's Imfinzi
- U.S. Stock Futures Drop as Oil Prices Rise Above $100 Amid U.S.-Iran Tensions
- S&P Futures Decline as Oil Prices Rise and Tensions Escalate in the Middle East
- Stocks Decline on Rising Oil Prices and Ongoing Trade Tensions
- Dow Jones Falls Sharply Due to Novartis' Failed Drug Trials
- Novartis, Amgen Shares Drop After Disappointing Clinical Trial Results
- Amgen Shares Drop Amid Mixed News from Lp(a) Trials and BMO Downgrade
- U.S. Stock Indexes Drop as Traders Worry Over Potential Rate Hike; Oil Prices Rise
- Stocks Slide Amid Rising Oil Prices and Geopolitical Tensions
- Lilly Holds Up Amid Drug Stock Declines; Boeing Reports Mixed Delivery Results
- Amgen Shares Drop After Novartis Fails Cholesterol Drug Trial
- Novartis' Cholesterol Drug Fails in Cardiovascular Trial, Casting Doubt on Lp(a) Treatment Race